Expert opinion on drug metabolism & toxicology · 2026
A systematic review of oral cancer drug therapies after metabolic bariatric surgery: what oncologists need to know about altered pharmacokinetics.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Phan Aurélie, Bastien Etienne, Carette Claire, Launay Manon
Аннотация
INTRODUCTION: Metabolic bariatric surgery (MBS) may substantially alter the pharmacokinetics of orally administered drugs, yet its impact on oral cancer drug therapies remains poorly characterized. We conducted a systematic review to synthesize the available evidence on the pharmacokinetics of oral anticancer drugs after MBS and identify practical implications for clinical management.
AREA COVERED: The search was performed on 6 February 2026, in PubMed, Embase and ClinicalTrials.gov. Studies reporting pharmacokinetic outcomes of oral anticancer agents after Roux-en-Y gastric bypass, sleeve gastrectomy, or one-anastomosis gastric bypass were included. Owing to heterogeneity in study design, drugs, and pharmacokinetic outcomes, a qualitative synthesis was performed. Eight studies involving 33 patients and 14 oral anticancer agents were included. Exposure was generally preserved for several biopharmaceutics classification system (BCS) class-I drugs, whereas BCS class-II drugs more frequently exhibited reduced exposure, including pazopanib, sorafenib, and tamoxifen. However, substantial interindividual variability was observed across all BCS-classes, and both under- and overexposure were reported.
EXPERT OPINION: Current evidence is scarce and of low certainty. BCS classification may assist in risk stratification, but does not reliably predict post-bariatric drug exposure. Therapeutic drug monitoring should be considered whenever available. Prospective longitudinal pharmacokinetic studies are urgently needed to establish evidence-based dosing recommendations in this growing patient population.
REGISTRATION: PROSPERO registration number: CRD420261300203.
AREA COVERED: The search was performed on 6 February 2026, in PubMed, Embase and ClinicalTrials.gov. Studies reporting pharmacokinetic outcomes of oral anticancer agents after Roux-en-Y gastric bypass, sleeve gastrectomy, or one-anastomosis gastric bypass were included. Owing to heterogeneity in study design, drugs, and pharmacokinetic outcomes, a qualitative synthesis was performed. Eight studies involving 33 patients and 14 oral anticancer agents were included. Exposure was generally preserved for several biopharmaceutics classification system (BCS) class-I drugs, whereas BCS class-II drugs more frequently exhibited reduced exposure, including pazopanib, sorafenib, and tamoxifen. However, substantial interindividual variability was observed across all BCS-classes, and both under- and overexposure were reported.
EXPERT OPINION: Current evidence is scarce and of low certainty. BCS classification may assist in risk stratification, but does not reliably predict post-bariatric drug exposure. Therapeutic drug monitoring should be considered whenever available. Prospective longitudinal pharmacokinetic studies are urgently needed to establish evidence-based dosing recommendations in this growing patient population.
REGISTRATION: PROSPERO registration number: CRD420261300203.